Stocks › BNTX

BioNTech SE

BNTX·Nasdaq·Germany Germany·USD
$80.96
-0.42 (-0.52%)
Close · Nov 20, 2026 · Close Prices from Tiingo.com
BNTX
BioNTech SE · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
BNTXS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair

Congressional Trades

Recent trades of BNTX by members of U.S. Congress · 8 on record
All congressional trades →
PoliticianStockTypeFiledTraded
Val T. HoyleVal T. HoyleHouse · D · OR BNTXBioNTech SE · Stock Sale
$1,001 - $15,000
Sep 12, 2025 Aug 7, 2025 Filing ↗
Josh GottheimerJosh GottheimerHouse · D · NJ BNTXBioNTech SE · Stock Sale
$1,001 - $15,000
Oct 3, 2024 Sep 3, 2024 Filing ↗
Josh GottheimerJosh GottheimerHouse · D · NJ BNTXBioNTech SE · Stock Sale
$1,001 - $15,000
Sep 11, 2024 Aug 30, 2024 Filing ↗
Josh GottheimerJosh GottheimerHouse · D · NJ BNTXBioNTech SE · Stock Purchase
$1,001 - $15,000
May 15, 2024 Apr 15, 2024 Filing ↗
Josh GottheimerJosh GottheimerHouse · D · NJ BNTXBioNTech SE · Stock Sale
$1,001 - $15,000
Apr 7, 2024 Mar 14, 2024 Filing ↗
Josh GottheimerJosh GottheimerHouse · D · NJ BNTXBioNTech SE · Stock Purchase
$1,001 - $15,000
Jan 7, 2024 Dec 6, 2023 Filing ↗
Josh GottheimerJosh GottheimerHouse · D · NJ BNTXBioNTech SE · Stock Purchase
$1,001 - $15,000
Jan 7, 2024 Dec 5, 2023 Filing ↗
Josh GottheimerJosh GottheimerHouse · D · NJ BNTXBioNTech SE · Stock Purchase
$1,001 - $15,000
Jan 7, 2024 Dec 7, 2023 Filing ↗

Whale Activity

Position changes in BNTX reported for 2026-09-30 by 336 institutional filers
Increased: 90New: 55Held: 59Decreased: 86Closed: 33No prior filing: 13
  • Increased90
  • New55
  • Held59
  • Decreased86
  • Closed33
  • No prior filing13
FilerSharesValueChange
FMR LLC9.8M$963.1Mincreased
PRIMECAP MANAGEMENT CO/CA/3.8M$368.9Mdecreased
DODGE & COX3.7M$362.5Mincreased
BlackRock, Inc.1.8M$180.4Mdecreased
BNP PARIBAS FINANCIAL MARKETS1.3M$126.0Mdecreased
T. Rowe Price Investment Management, Inc.1.2M$121.9Mdecreased
Temasek Holdings (Private) Ltd1.2M$121.5Mdecreased
FIRST TRUST ADVISORS LP996.3K$97.9Mincreased
D. E. Shaw & Co., Inc.974.9K$95.8Mincreased
GOLDMAN SACHS GROUP INC863.7K$84.9Mincreased
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC800.9K$78.7Mincreased
Assenagon Asset Management S.A.760.7K$74.8Mincreased

Every 13F filer's complete reported book, every quarter since 2013-06-30. 13F itself excludes short positions, cash and most options.

Insider Trading

Net shares bought (+) or sold (−) on the open market by BNTX insiders, by quarter · Form 4
-1.0M-500.0K0500.0K1.0M2025 Q1: 02025 Q12025 Q2: 02025 Q22025 Q3: 02025 Q32025 Q4: 02025 Q42026 Q1: 02026 Q12026 Q2: -50.0K2026 Q22026 Q3: -644.0K2026 Q32026 Q4: -214.2K2026 Q4

Recent Insider Transactions

27 transactions on record · newest first
All insider activity →
InsiderTypeSharesPriceValueDate
Sahin UgurChief Executive Officer Sale −36.2K $95.37 $3.5M Oct 9, 2026 Form 4 ↗
Sahin UgurChief Executive Officer Sale −27.0K $92.31 $2.5M Oct 8, 2026 Form 4 ↗
Sahin UgurChief Executive Officer Sale −24.0K $95.86 $2.3M Oct 7, 2026 Form 4 ↗
Sahin UgurChief Executive Officer Sale −21.0K $96.81 $2.0M Oct 6, 2026 Form 4 ↗
Sahin UgurChief Executive Officer Sale −72.0K $97.23 $7.0M Oct 5, 2026 Form 4 ↗
Sahin UgurChief Executive Officer Sale −17.0K $96.72 $1.6M Oct 2, 2026 Form 4 ↗
Sahin UgurChief Executive Officer Sale −17.0K $97.46 $1.7M Oct 1, 2026 Form 4 ↗
Sahin UgurChief Executive Officer · 10% owner Sale −32.0K $98.12 $3.1M Sep 30, 2026 Form 4 ↗
Sahin UgurChief Executive Officer · 10% owner Sale −34.0K $98.26 $3.3M Sep 29, 2026 Form 4 ↗
Sahin UgurChief Executive Officer · 10% owner Sale −34.0K $98.47 $3.3M Sep 28, 2026 Form 4 ↗
Sahin UgurChief Executive Officer · 10% owner Sale −27.0K $98.69 $2.7M Sep 25, 2026 Form 4 ↗
Sahin UgurChief Executive Officer · 10% owner Sale −39.0K $98.99 $3.9M Sep 24, 2026 Form 4 ↗
Sahin UgurChief Executive Officer · 10% owner Sale −30.0K $99.40 $3.0M Sep 23, 2026 Form 4 ↗
Sahin UgurChief Executive Officer · 10% owner Sale −46.0K $100.72 $4.6M Sep 22, 2026 Form 4 ↗
Sahin UgurChief Executive Officer · 10% owner Sale −33.0K $97.81 $3.2M Sep 21, 2026 Form 4 ↗
Sahin UgurChief Executive Officer · 10% owner Sale −30.0K $96.22 $2.9M Sep 18, 2026 Form 4 ↗
Sahin UgurChief Executive Officer · 10% owner Sale −34.0K $98.60 $3.4M Sep 17, 2026 Form 4 ↗
Sahin UgurChief Executive Officer · 10% owner Sale −15.0K $96.09 $1.4M Sep 16, 2026 Form 4 ↗
Sahin UgurChief Executive Officer · 10% owner Sale −34.0K $96.49 $3.3M Sep 15, 2026 Form 4 ↗
Sahin UgurChief Executive Officer · 10% owner Sale −41.0K $99.45 $4.1M Sep 14, 2026 Form 4 ↗

Fund Holders

Mutual funds and ETFs holding BNTX · SEC Form N-PORT
FundSharesValue% of fundAs of
Fidelity Contrafund3.3M$305.0M0.17%Jun 30, 2026
Dodge & Cox International Stock Fund
Dodge & Cox Funds
2.5M$234.3M0.35%Jun 30, 2026
T. Rowe Price Mid-Cap Growth Fund, Inc.1.0M$94.8M0.41%Jun 30, 2026
PRIMECAP Odyssey Aggressive Growth Fund
PRIMECAP Odyssey Funds
897.2K$81.3M1.10%Jul 31, 2026
First Trust NYSE Arca Biotechnology Index Fund
First Trust Exchange-Traded Fund
794.7K$73.9M2.63%Jun 30, 2026
Fidelity Contrafund K6
Fidelity Contrafund
704.5K$65.6M0.17%Jun 30, 2026
iShares Biotechnology ETF
iShares Trust
647.1K$60.2M0.66%Jun 30, 2026
Fidelity Emerging Markets Fund
Fidelity Investment Trust
660.8K$59.9M0.55%Jul 31, 2026
Dodge & Cox Global Stock Fund
Dodge & Cox Funds
525.8K$48.9M0.38%Jun 30, 2026
MFS Mid Cap Value Fund
MFS SERIES TRUST XI
487.2K$45.3M0.26%Jun 30, 2026

Mutual funds and ETFs whose N-PORT filings list BNTX's shares (CUSIP 09075V102), each fund at its latest report since Apr 22, 2026, largest positions first. Bonds, options and short positions are left out.

Activist & Passive Stakes

Schedule 13D / 13G beneficial-ownership filings
  • Thomas MaierSCHEDULE 13G/A · passive (13G) · 101.7M shares40.2%
    May 14, 2026 · ↗
  • AT Impf GmbHSCHEDULE 13G/A · passive (13G) · 101.7M shares40.2%
    May 14, 2026 · ↗
  • ATHOS KGSCHEDULE 13G/A · passive (13G) · 101.7M shares40.2%
    May 14, 2026 · ↗

Corporate Lobbying

Estimated quarterly lobbying spending reported under the LDA, filings naming BioNTech SE as client

No lobbying filings found naming BioNTech SE as the client.

Government Contracts

Federal awards to BioNTech SE · USAspending

No federal contract awards found for BioNTech SE.

U.S. Patents

Recent USPTO applications naming BioNTech SE

No USPTO patent applications found for BioNTech SE.

Annual Financials

From BNTX's 10-K filings · XBRL

SEC's XBRL figures for BioNTech SE include no full-year results from a 10-K in US dollars, so there is no table to show. Companies based abroad usually report annually on Form 20-F instead.

Stock Splits

Every split and reverse split in the price history

No stock splits in BNTX's price history.

Material Events (8-K)

Corporate events filed with the SEC

No 8-K filings on record.

About BioNTech SE

From SEC EDGAR company records
Industry (SIC 2836)Biological Products, (No Diagnostic Substances)
SectorHealthcare
HeadquartersMAINZ, Germany
Incorporated2M